[go: up one dir, main page]

MX2018005925A - Purinonas como inhibidores de proteasa específica de ubiquitina 1. - Google Patents

Purinonas como inhibidores de proteasa específica de ubiquitina 1.

Info

Publication number
MX2018005925A
MX2018005925A MX2018005925A MX2018005925A MX2018005925A MX 2018005925 A MX2018005925 A MX 2018005925A MX 2018005925 A MX2018005925 A MX 2018005925A MX 2018005925 A MX2018005925 A MX 2018005925A MX 2018005925 A MX2018005925 A MX 2018005925A
Authority
MX
Mexico
Prior art keywords
purinones
ubiquitin
inhibitors
specific protease
usp1
Prior art date
Application number
MX2018005925A
Other languages
English (en)
Other versions
MX379543B (es
Inventor
A Caravella Justin
Ioannidis Stephanos
Gustafson Gary
Wang Zhongguo
Lin Jian
Follows Bruce
Joseph Buckmelter Alexandre
Wang Minghua
L Fritzen Edward
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2018005925A publication Critical patent/MX2018005925A/es
Publication of MX379543B publication Critical patent/MX379543B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La solicitud se refiere a inhibidores de USP1 útiles en el tratamiento de canceres, y otras enfermedades y trastornos asociados con USP1. Con la Formula: Donde R1, R2, R3, R4, R5, X1, X2, X3, X4, y n se describen en la presente.
MX2018005925A 2015-11-20 2016-11-18 Purinonas como inhibidores de proteasa específica de ubiquitina 1. MX379543B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258162P 2015-11-20 2015-11-20
PCT/US2016/062837 WO2017087837A1 (en) 2015-11-20 2016-11-18 Purinones as ubiquitin-specific protease 1 inhibitors

Publications (2)

Publication Number Publication Date
MX2018005925A true MX2018005925A (es) 2019-03-28
MX379543B MX379543B (es) 2025-03-11

Family

ID=57472109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001186A MX2021001186A (es) 2015-11-20 2016-11-18 Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2018005925A MX379543B (es) 2015-11-20 2016-11-18 Purinonas como inhibidores de proteasa específica de ubiquitina 1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021001186A MX2021001186A (es) 2015-11-20 2016-11-18 Purinonas como inhibidores de proteasa especifica de ubiquitina 1.

Country Status (13)

Country Link
US (4) US10189841B2 (es)
EP (2) EP3696181A1 (es)
JP (3) JP6964343B2 (es)
KR (1) KR102708936B1 (es)
CN (2) CN114702495A (es)
AU (3) AU2016356694B2 (es)
BR (1) BR112018010216B1 (es)
CA (1) CA3005353A1 (es)
IL (3) IL300788A (es)
MX (2) MX2021001186A (es)
RU (1) RU2750151C2 (es)
SG (1) SG11201804098TA (es)
WO (1) WO2017087837A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
ES3040707T3 (en) 2017-11-01 2025-11-04 Dana Farber Cancer Inst Inc Usp1 or uaf1 inhibitors for use in treating cancer
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MA53275A (fr) * 2018-08-09 2021-09-15 Valo Early Discovery Inc Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine
CN109503421B (zh) * 2018-11-20 2022-10-14 黎明化工研究设计院有限责任公司 一种提高叠氮胺燃料合成过程安全性的方法
JP7662519B2 (ja) * 2018-12-20 2025-04-15 ケーエスキュー セラピューティクス, インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用
CN113474346B (zh) * 2018-12-28 2024-12-27 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物
CN113924296B (zh) * 2019-05-31 2024-09-17 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生化合物及包含其的药物组合物
US12440484B2 (en) 2019-05-31 2025-10-14 Chong Kun Dang Pharmaceutical Corporation 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN110759902B (zh) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
WO2021237111A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
US20230219965A1 (en) * 2020-06-02 2023-07-13 KSQ Therapeutics, Inc. Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
KR102458689B1 (ko) * 2020-07-08 2022-10-25 원광대학교산학협력단 피페리딘 화합물 및 이의 제조 방법
KR102685058B1 (ko) * 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
CN111926018B (zh) * 2020-09-04 2022-07-12 首都医科大学附属北京儿童医院 降低usp1表达的物质在制备治疗儿童t系急性淋巴细胞白血病的药物中的应用
EP4236958A4 (en) 2020-10-30 2024-09-11 KSQ Therapeutics, Inc. SOLID STATE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND THEIR USES
WO2022197892A1 (en) * 2021-03-17 2022-09-22 Tango Therapeutics, Inc. Purine derivatives as anticancer agents
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
MA62912A1 (fr) * 2021-04-07 2024-05-31 Forma Therapeutics Inc Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)
CN117136189A (zh) * 2021-04-09 2023-11-28 先声再明医药有限公司 泛素特异性蛋白酶1(usp1)抑制剂
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
CA3235328A1 (en) * 2021-10-18 2023-04-27 Jianwei Che Covalent egfr inhibitors and methods of use thereof
WO2023086521A1 (en) * 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
PE20241234A1 (es) * 2021-11-12 2024-06-19 Insilico Medicine Ip Ltd Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos
KR20240117556A (ko) * 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
CA3235603A1 (en) * 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2023148643A1 (en) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Fused bicyclic heterocyclyl compounds as usp1 inhibitors
CA3250418A1 (en) * 2022-04-29 2025-07-08 Asieris Pharmaceuticals (Shanghai) Co., Ltd. PYRIMIDINE COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE
CN119731178A (zh) * 2022-06-23 2025-03-28 福马治疗有限公司 Usp1抑制剂及其用途
EP4547336A1 (en) * 2022-06-29 2025-05-07 Zentaur Therapeutics USA Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
CN119790043A (zh) * 2022-08-26 2025-04-08 海南先声再明医药股份有限公司 三环类化合物及其应用
TW202411231A (zh) * 2022-09-09 2024-03-16 大陸商正大天晴藥業集團股份有限公司 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
AU2023343945A1 (en) * 2022-09-20 2025-04-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Carbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor
CN120092007A (zh) * 2022-10-09 2025-06-03 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
WO2024153175A1 (en) 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Heteroaromatic compounds and their use as usp1 inhibitors
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN116621846B (zh) * 2023-07-24 2023-10-17 华润医药研究院(深圳)有限公司 双环杂环及三环杂环类化合物及其制备方法和医药用途
WO2025067259A1 (zh) * 2023-09-26 2025-04-03 上海济煜医药科技有限公司 一类氮杂环胺类化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Dna損傷修復途徑的新穎抑制劑
CN119707772B (zh) * 2024-12-23 2025-09-02 浙江大学 一种usp14共价抑制剂及其制备方法和应用

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440929A (en) 1981-07-16 1984-04-03 Usv Pharmaceutical Corporation Imidazoquinoxaline compounds
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
IL90315A0 (en) 1988-06-01 1989-12-15 Ferrosan As Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
DK626288D0 (da) 1988-11-10 1988-11-10 Ferrosan As Kemisk proces til fremstilling af imidazoquinoxaliner og mellemprodukter til brug i processen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
DK588489D0 (da) 1989-11-22 1989-11-22 Ferrosan As Heterocykliske forbindelser, deres fremstilling og anvendelse
WO1992022552A1 (en) 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
AU4035893A (en) 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
EP0626966A1 (en) 1992-02-19 1994-12-07 PHARMACIA & UPJOHN COMPANY 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
WO2001049688A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
JP3675274B2 (ja) 2000-01-27 2005-07-27 ダイソー株式会社 9−(2−ヒドロキシアルキル)プリン誘導体および1−(2−ヒドロキシアルキル)ピリミジン誘導体の製造法
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
AU2001271867A1 (en) 2000-07-07 2002-01-21 Neotherapeutics, Inc. Methods for treatment of conditions affected by activity of multidrug transporters
EP1334104A2 (en) 2000-07-07 2003-08-13 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
US20020040031A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US20020091133A1 (en) 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
WO2003068776A1 (en) 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
US7371857B2 (en) 2002-08-08 2008-05-13 Valeant Research & Development Synthesis for hydroxyalkylated heterocyclic bases
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
JP2004217582A (ja) 2003-01-16 2004-08-05 Abbott Japan Co Ltd 9h−プリン誘導体
US20040180898A1 (en) 2003-03-03 2004-09-16 Bang-Chi Chen Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
DE602004007387T2 (de) 2003-07-02 2008-03-06 F. Hoffmann-La Roche Ag 5-substituierte chinazolinonderivate
MXPA06000700A (es) 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005112935A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Cgrp 수용체 길항제
SI1848718T1 (sl) 2005-02-04 2012-12-31 Millennium Pharmaceuticals, Inc. Inhibitorji E1 aktivacijskih enzimov
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
RU2007140903A (ru) 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US20090023723A1 (en) 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
DE102005062987A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
WO2007139992A2 (en) 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US7754463B2 (en) 2006-06-20 2010-07-13 Dana-Farber Cancer Institute Inhibitors of USP1 Deubiquitinating Enzyme Complex
WO2008079460A2 (en) * 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
WO2008030744A2 (en) * 2006-09-05 2008-03-13 Board Of Regents, The University Of Texas System Inhibitors of c-met and uses thereof
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
US7968556B2 (en) * 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
MX2009005194A (es) 2006-11-16 2009-11-10 Pharmacopeia Llc Derivados de purina 7-sustituidos para inmunosupresion.
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP2010522177A (ja) 2007-03-23 2010-07-01 アムジエン・インコーポレーテツド 複素環化合物およびその使用
WO2008117796A1 (ja) 2007-03-28 2008-10-02 Dainippon Sumitomo Pharma Co., Ltd. 新規ムチリン誘導体
US20090182035A1 (en) 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
JP2010523695A (ja) 2007-04-11 2010-07-15 アルコン リサーチ, リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのTNFαのインヒビターおよび抗ヒスタミン薬の使用
GB0708258D0 (en) 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs
WO2008131501A2 (en) 2007-04-27 2008-11-06 Katholieke Universiteit Leuven New anti-viral nucleoside analogs
CN101679412A (zh) 2007-05-23 2010-03-24 药典有限责任公司 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2705834A1 (en) 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
WO2009068246A2 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
CN101918408A (zh) 2007-11-30 2010-12-15 惠氏有限责任公司 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
WO2009090054A1 (en) 2008-01-17 2009-07-23 Grünenthal GmbH Substituted sulfonamide derivatives
CA2712266A1 (en) 2008-01-17 2009-07-23 Gruenenthal Gmbh Substituted sulfonamide derivatives
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009117283A2 (en) 2008-03-21 2009-09-24 Merck & Co., Inc. Quinolizidinone m1 receptor positive allosteric modulators
CA2722308C (en) 2008-04-15 2024-02-27 Rfs Pharma, Llc. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
EP2303876B1 (en) 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
JP5662319B2 (ja) 2008-09-09 2015-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アザ−ベンゾイミダゾロンキマーゼ阻害剤
EP2334672B1 (en) 2008-09-16 2013-11-20 Proximagen Limited 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US8835422B2 (en) 2008-12-11 2014-09-16 Cara Therapeutics, Inc. Substituted imidazoheterocycle derivatives
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
PE20121352A1 (es) 2009-10-29 2012-10-15 Palau Pharma Sa Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのlkb1変異の同定
US9518032B2 (en) 2010-04-30 2016-12-13 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of USP1 deubiquitinating enzyme activity
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
JP2012012332A (ja) 2010-06-30 2012-01-19 Dainippon Sumitomo Pharma Co Ltd 新規アザインドール誘導体
WO2012003576A1 (en) 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
JP5995956B2 (ja) 2011-03-26 2016-09-21 フォルム ファーマシューティカルズ、インコーポレイテッド 前頭側頭葉変性症の標的治療の方法
US20140005164A1 (en) 2011-04-04 2014-01-02 Siena Biotech S.P.A. Wnt pathway antagonists
WO2013025628A1 (en) 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
US9338896B2 (en) 2012-07-25 2016-05-10 Enthone, Inc. Adhesion promotion in printed circuit boards
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
WO2014043246A1 (en) 2012-09-11 2014-03-20 The Board Of Trustees Of The University Of Illinois Enoyl reductase inhibitors with antibacterial activity
AU2013202768B2 (en) * 2012-10-18 2015-11-05 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
JP6024979B2 (ja) 2013-02-21 2016-11-16 学校法人金沢工業大学 難燃組成物、それを用いた難燃化処理方法および難燃材料
CN103923085B (zh) 2013-02-25 2016-08-24 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
JP2016516671A (ja) 2013-02-28 2016-06-09 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤を用いたがんの治療
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
MX2015012432A (es) 2013-03-13 2016-02-05 Abbvie Inc Inhibidores piridinicos de la cinasa cdk9.
US20160039825A1 (en) 2013-03-15 2016-02-11 Biogen Ma Inc. S1p and/or atx modulating agents
EP2978425B1 (en) 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN106467538B (zh) 2015-08-14 2019-03-05 沈阳中化农药化工研发有限公司 一种取代的四氢异喹啉化合物与用途
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
CN107629057B (zh) 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
CN107629071B (zh) 2016-07-19 2019-12-27 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7662519B2 (ja) 2018-12-20 2025-04-15 ケーエスキュー セラピューティクス, インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用
CN113474346B (zh) 2018-12-28 2024-12-27 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物

Also Published As

Publication number Publication date
AU2021257988B2 (en) 2023-12-21
IL282103A (en) 2021-05-31
JP7650854B2 (ja) 2025-03-25
AU2016356694B2 (en) 2021-07-29
JP7273886B2 (ja) 2023-05-15
BR112018010216A2 (pt) 2018-11-21
US10189841B2 (en) 2019-01-29
WO2017087837A1 (en) 2017-05-26
US11161848B2 (en) 2021-11-02
KR102708936B1 (ko) 2024-09-25
US20170145012A1 (en) 2017-05-25
IL259220A (en) 2018-07-31
JP2023011899A (ja) 2023-01-24
US12043623B2 (en) 2024-07-23
US20220281869A1 (en) 2022-09-08
SG11201804098TA (en) 2018-06-28
JP6964343B2 (ja) 2021-11-10
RU2750151C2 (ru) 2021-06-22
RU2018121499A3 (es) 2020-01-21
EP3696181A1 (en) 2020-08-19
JP2019504821A (ja) 2019-02-21
US10399980B2 (en) 2019-09-03
JP2021113224A (ja) 2021-08-05
AU2023274204A1 (en) 2023-12-21
IL282103B2 (en) 2023-08-01
AU2016356694A1 (en) 2018-07-05
AU2021257988A1 (en) 2021-12-09
MX2021001186A (es) 2022-10-11
US20180339986A1 (en) 2018-11-29
IL259220B (en) 2021-04-29
CN108473495A (zh) 2018-08-31
EP3377493B1 (en) 2020-04-08
NZ743551A (en) 2024-11-29
EP3377493A1 (en) 2018-09-26
CA3005353A1 (en) 2017-05-26
CN114702495A (zh) 2022-07-05
IL282103B1 (en) 2023-04-01
MX379543B (es) 2025-03-11
US20200079776A1 (en) 2020-03-12
IL300788A (en) 2023-04-01
RU2018121499A (ru) 2019-12-20
CN108473495B (zh) 2022-04-12
KR20180095539A (ko) 2018-08-27
BR112018010216B1 (pt) 2024-02-15

Similar Documents

Publication Publication Date Title
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
ECSP17049010A (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
NZ736665A (en) Heterocyclic amides as kinase inhibitors
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX2015010125A (es) Derivados de piridazinona-amidas.
MX381417B (es) Inhibidores de glucosidasa.
HK1248221A1 (zh) 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
MX373549B (es) Derivado de pirazol amida.
CL2015002897A1 (es) Inhibidores de bace1
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
MX373603B (es) Activador de canales de kcnq2-5.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
TW201612253A (en) High wet fast disperse dyes and mixtures thereof